The clinical trial, sponsored by the University of Minnesota, aims to evaluate the efficacy of phentermine/topiramate in preventing obesity in adolescents aged 16 to 22 with a BMI of 25-30 kg/m² and a family history of obesity. The trial has been withdrawn due to lack of funding, which raises concerns regarding the feasibility of further development. The obesity pharmacotherapy market is competitive, with established players and emerging therapies. The withdrawal of this trial may limit the potential for phentermine/topiramate as a preventive treatment in this demographic, impacting market positioning and investor confidence. Further diligence is required to assess alternative funding avenues or partnerships to revive the study.